---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000037"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:56:19.245357+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction

## Summary
- MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).
- Minimal Symptom Expression (MSE) at Week 12: 42% for 680mg, 31% for 340mg, 7% placebo.
- CIDP Phase 2b Period 1: 1.8-point aINCAT improvement; 84% responder rate among patients with ≥70% IgG reduction.
- Company will not seek batoclimab approval in MG/CIDP; focusing on IMVT-1402 and awaiting thyroid eye disease data.
- IND cleared for IMVT-1402 in MG and CIDP; registrational studies expected to start imminently.

## SEC filing metadata
- accession: 0001764013-25-000037
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000037/0001764013-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000037/imvt-20250319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000037
- JSON: https://secwatch.observer/filing/0001764013-25-000037.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.